nimotuzumab
biocon,daiichi sankyo,oncoscience
['nimotuzumab', 'gi ', 'pancsm', 'pancreatic']
 happening now:
can we begin to predict responders to targeted therapy in gi cancer lba4011 nimotuzumab combined with gemcitabine vs. gemcitabine in k-ras wild-type locally advanced or metastatic pancreatic cancer. #pancsm hall d1
#asco22
@UconnIM | HemOnc @AUBMC_Official | @USEKofficial Alumni | @ASCO SM Editor @JCOGO_ASCO | VTP Award @ASH_Hematology | Views are my own FCOI: https://t.co/nLxBFc8CcY